Suchergebnisse - Portal für Medizinische Datenmodelle (MDM-Portal)

Suchergebnisse filtern
Datenmodelle auswählen

Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

97 Suchergebnisse.

Phonak EduLink Speech-in-Noise Intelligibility Eligibility DRKS00005520 NCT00167128 - Eligibility Speech-in-Noise Intelligibility NCT00167128

- 05.06.15 - 1 Formular, 2 Itemgruppen, 8 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00167128?term=NCT00167128&rank=1 The Phonak EduLink-System in Students With Specific Performance Deficits in Speech-in-Noise Intelligibility Eligibility NCT00167128 speech-in-noise intelligib

Eligibility NCT00148161 # Stuttering - Eligibility

- 11.12.13 - 1 Formular, 3 Itemgruppen, 22 Datenelemente, 2 Sprachen

Itemgruppen: Inclusion criteria, Exclusion criteria, Medical Concepts

The goal of the study is to examine the cortical activity during speech perception and speech production in idiopathic stutterers compared to fluent speakers. Therefore, the noninvasive method of magnetoencephalography (MEG) is used. A better understanding for the complexity of speech perception and its pathology should be developed. Fundamental properties of stuttering are repetitions, prolongations, and blocks. In most cases stuttering emerges between 2 and 5 years of age. The auditory feedback should become less important during development, as soon as information about mispronounced words does not occur anymore. During speech development this control function should be adopted by other systems. In stutterers the dominance of the acoustic control should remain. Brain imaging studies with positron emission tomography (PET) or magnetic resonance imaging (MRI) show defects in the network of motor system, in the lateralization of speech areas, and functions of the auditory cortex. Magnetoencephalographic studies describe a similar variety as cause of stuttering. There may be defects in the auditory feedback, a modification of the lateralization of speech areas, or an alteration of co-action of motor planning and auditory system. The benefit of magnetoencephalography is a very good temporal resolution in the range of milliseconds combined with good spatial resolution. Therefore, it is well suited to examine the dynamics of cortical processing during stuttering. In this study evoked components of the auditory systems related to complex sounds, vocals, consonant-vocal combinations, and single words are analyzed. Differences of these components in the auditory cortices of stutterers and fluent speakers are hypothesized as well in temporal structure as in localization and lateralization.

Eligibility DRKS00005561 NCT00508664 Squamous Cell Carcinoma of the Hypopharynx - Eligibility

- 20.09.21 - 1 Formular, 2 Itemgruppen, 31 Datenelemente, 2 Sprachen

Itemgruppen: Inclusion Criteria, Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00508664

Eligibility Apraxia DRKS00012292 NCT03185234 DRKS00012292 - Eligibility Apraxia NCT03185234 DRKS00012292

- 04.07.17 - 1 Formular, 2 Itemgruppen, 19 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

Responsible Party: Gereon R. Fink, Univ.-Prof. Dr. med., University of Cologne ClinicalTrials.gov Identifier: NCT03185234 History of Changes Other Study ID Numbers: Uni-Koeln-3033 U1111-1195-2536 ( Other Identifier: WHO ) DRKS00012292 ( Registry Identifier: DRKS ) Study First Received: May 31, 2017 Last Updated: June 23, 2017 Rehabilitating (Stroke-induced) Apraxia With Direct Current Stimulation (RAdiCS) ODM derived from: https://clinicaltrials.gov/ct2/show/NCT03185234

Eligibility Asthma NCT02501824

- 19.04.16 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

Effectiveness of Anthroposophic Speech Therapy in Patients With Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT02501824

Eligibility Parkinson's Disease NCT01636011

- 13.01.19 - 1 Formular, 2 Itemgruppen, 9 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

Effect of Osteopathic Manipulative Medicine (OMM) on Pulmonary Function and Speech in Parkinson's Disease; ODM derived from: https://clinicaltrials.gov/show/NCT01636011

Eligibility Syncope NCT01965899

- 28.09.21 - 1 Formular, 2 Itemgruppen, 15 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

Usability Study to Assess the Reveal LINQ Insertable Cardiac Monitor System; ODM derived from: https://clinicaltrials.gov/show/NCT01965899

Hib-MenAC vaccine administered intramuscularly in infants at 6 10 and 14 weeks of age - 104430 - Visit 5 ( Month 7.5)

- 15.03.21 - 1 Formular, 8 Itemgruppen, 30 Datenelemente, 1 Sprache

Itemgruppen: Administrative data, ELIMINATION CRITERIA DURING THE STUDY, Contraindications and precautions for further doses, DEMOGRAPHICS, PRE-VACCINATION ASSESSMENT, THROAT SWAB (for subject’s parents/guardians), THROAT SWAB (for subject), VACCINE ADMINISTRATION

Study ID: 104430 Clinical Study ID: 104430 Study Title: A phase II, double blind, randomized, controlled study to evaluate the immunogenicity, reactogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ Hib-MenAC vaccine, extemporaneously mixed with GSK Biologicals’ Tritanrix-HepB, as compared to GSK Biologicals’ Hiberix vaccine, extemporaneously mixed with GSK Biologicals’ Tritanrix-HepB, when administered intramuscularly in infants at 6, 10 and 14 weeks of age. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1/2 Study Recruitment Status: Completed Generic Name: Hib-MenAC vaccine Trade Name: Tritanrix-HepB, Hiberix Study Indication: Immune, Inflammatory & Infections - Other

Eligibility Carcinoma, Squamous Cell NCT00671437

- 27.09.21 - 1 Formular, 2 Itemgruppen, 12 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00671437

Eligibility Carcinoma, Squamous Cell of the Head and Neck NCT00753038

- 27.09.21 - 1 Formular, 2 Itemgruppen, 16 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00753038

Eligibility Head and Neck Squamous Carcinoma NCT00634595

- 17.09.21 - 1 Formular, 2 Itemgruppen, 13 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

Trial of E10A in Head and Neck Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00634595

Eligibility Head and Neck Squamous Cell Carcinoma NCT00957853

- 11.06.20 - 1 Formular, 2 Itemgruppen, 15 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

Preoperative Treatment With Cetuximab and/or IMC-A12; ODM derived from: https://clinicaltrials.gov/show/NCT00957853

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.